Loading Events
Find Events

Event Views Navigation

Upcoming Events

Events List Navigation

July 2017

The 12th World Congress on Neurohypophysial Hormones

July 26 - July 29
Porto Real Resort, Rodovia s/n km 450, BR-101 - Nova Mangaratiba
Mangaratiba , RJ 23860-000 Brazil

Jointly with the International Advisory Committee, we are putting an exciting programme that will span all aspects of oxytocin and vasopressin research from cellular physiology to behaviour. The most recent advances in the field will be presented by leading researchers. There will also be ample opportunity for new and emerging researchers to present their work as part of symposiums, oral presentation programme or at the poster session.

At this time, we invite you to submit proposals for Symposia at WCNH 2017. All proposals must be submitted through the e-mail 12thwcnh@gmail.com from now up to 31 October 2016. The proposals should follow this template form. The submitted symposia proposals will be evaluated by the Local Organizing and the International Advisory Committees, and the selected ones will be announced by 15 November 2016.

Find out more »

Cycle 3: Alzheimer’s Drug Discovery Foundation

July 31

LOI DUE JULY 31, 2017
Preclinical Drug Discovery
Seeks to fund promising preclinical drug discovery and biomarker development programs for Alzheimer’s disease, related dementias and cognitive aging. The ADDF typically supports one year of research at a time, with potential for future follow-on funding. Funding can range from $150,000-$600,000 for a preclinical project.
Program to Accelerate Clinical Trials (PACT)
Seeks to fund biomarker-based, proof-of-concept pilot clinical trials, as well as Phase 1 safety testing and IND-enabling studies to accelerate new drugs into trials. Up to $1.5 million.
Biomarkers Development
Seeks to support the development and validation of novel and existing biomarkers that will enhance the design and performance of clinical trials for Alzheimer’s disease, related dementias, and cognitive aging. $150,000-$300,000/year, 1-2 years.
Prevention Beyond the Pipeline
The ADDF seeks to support prevention drug discovery not covered by most research funders or our current RFPs. Funding can range from $50,000-$100,000 for epidemiological analyses, $150,000-$600,000 for preclinical research, and up to $1.5 million for clinical trials.
Accelerating Drug Discovery for Frontotemporal Degeneration
Seeks to accelerate and support innovative drug discovery programs for FTD in partnership with The Association for Frontotemporal Degeneration. Funding can range from $100,000-$150,000 per year, average one year duration.

Find out more »
August 2017

Foundation for Physical Therapy

August 3

DUE AUGUST 3, 2017, NOON EDT
Foundation Research Grant
Funds clinically relevant research by emerging investigators seeking to evaluate the effectiveness of physical therapy interventions. This grant will provide $40,000 for either one or two year projects.
Snyder Research Grant
One $40,000 SRG is to be awarded to support relevant clinical research projects aimed to investigate: a) those services delivered by physical therapists; and b) the development of new interventions that offer reasonable assurance that they will be clinically relevant and therapeutically effective.

Find out more »

Cycle 2: Ruth L. Kirschstein National Research Service Awards (F Series)

August 8

Sponsor: National Institutes of Health
Due Date: August 8, 2017
Award: Fellowship

Find out more »

Cycle 2: Conference Grants (R13) and Conference Cooperative Agreements (U13)

August 12

Sponsor: NIH
Due Date: August 12, 2017
Award: Funding for conferences

Find out more »

APS Conference: Physiological Bioenergetics: Mitochondria from Bench to Bedside

August 30 - September 1
U.S. Grant Hotel, 326 Broadway
San Diego, CA 92101 United States

In the last two decades it has become apparent that mitochondria perform a multitude of functions to maintain cellular homeostasis, all of which are intimately linked to bioenergetics. New cutting edge technology, novel molecular tools and mitochondrially targeted therapeutics developed in the past five years have made it possible to more accurately and deeply probe mitochondrial function and have dramatically altered the study of bioenergetics under physiological conditions.

Our knowledge of the mechanisms by which mitochondrial function is regulated and its contribution to cellular homeostasis is also rapidly expanding. However, these advances are generally made in the context of a specific pathology or organ system and are not always widely recognized by investigators studying a different pathology. Further, a great gap in knowledge still exists in translating mitochondrial measurement to human studies.

The goal of the “Physiological Bioenergetics- from Bench to Bedside” conference is to bring together experts studying varied facets of bioenergetics across disciplines and in the context of different pathologies to share their most recent findings and to discuss strategies to advance the field of “mitochondriology” into translational and clinical studies. This is a “”must attend”” conference for a researcher at any stage of their career who is interested in studying mitochondrial function or integrated bioenergetics.

Find out more »
September 2017

Cycle 1: BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42)

September 5

Sponsor: National Institutes of Health
Due Date: September 5, 2017 by 5 pm local time of applicant
Award: Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

Cycle 1: BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44)

September 5

Sponsor: National Institutes of Health
Due Date: September 5, 2017 by 5 pm local time of applicant
Award: Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

Cycle 1: Development of Novel and Emerging Technologies to Support Zebrafish Models for Biomedical Research (R43/R44)

September 5

Sponsor: National Institutes of Health
Due Date: September 5, 2017 by 5 pm local time of applicant
Award: Money, property, or both to an eligible entity to carry out an approved project or activity. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

Cycle 1: Development of Novel and Emerging Technologies to Support Zebrafish Models for Biomedical Research (R41/R42)

September 5

Sponsor: National Institutes of Health
Due Date: September 5, 2017 by 5 pm local time of applicant
Award: Money, property, or both to an eligible entity to carry out an approved project or activity. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

Cycle 3: Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities (R01)

September 5

Sponsor: NIH
LOI Due Date: September 5, 2017
Due Date: October 5, 201 by 5 pm local time of applicant
Award: Budgets for direct costs of up to $499,999 per year may be requested. Project period may not exceed 5 years.

Find out more »

Cycle 3: High Throughput Screening (HTS) to Discover Chemical Probes (R01)

September 5

Sponsor: National Institutes of Health
LOI Due Date: September 5, 2017
Application Due Date: October 5, 2017
Award: Actual needs 3 years

Find out more »

Cycle 1: Small Business Innovation Research (SBIR)

September 5

Sponsor: National Institutes of Health
Due Date: September 5, 2017
Award: Total costs for Phase I and Phase II usually do not exceed $1,150,000; no funding is provided for Phase III

Find out more »

Cycle 1: Small Business Technology Transfer (STTR)

September 5

Sponsor: National Institutes of Health
Due Date: September 5, 2017
Award: Total costs for Phase I and Phase II usually do not exceed $1,150,000; no funding is provided for Phase III

Find out more »

Exploring Human Host-Microbiome Interaction in Health and Disease

September 13 - September 15

“Recent studies have revealed the complexity of the gut microbial ecology and its network connectivity to the metabolic regulation of important pathways in the host. Studies on microbiota from various body sites are helping us to understand how microorganisms affect the host. Alterations in microbiome composition have been associated with many non-infectious diseases including inflammatory bowel conditions, autoimmune diseases, cancers and diabetes, although in many cases causality has yet to be established.

This meeting will update current knowledge of how various microbiomes (oral, gut, lung, non-bacterial etc.) communicate with the host and the factors that influence these interactions. The programme will discuss the new developments enabled by metagenomics, metabolomics and other technologies. Attendees will have the opportunity to participate in discussions on how to apply recent discoveries to disease processes, health restoration and maintenance. This year’s meeting will also include discussion sessions on faecal transplants and on the evidence required to prove causality in microbiome research. As in previous years, the warm welcome given to students and the open friendly atmosphere provide attendees with an enjoyable conference.”

Find out more »

World Congress of Neurology 2017

September 16 - September 21
Kyoto International Conference Center, ​Takaragaike, Sakyo-ku
Kyoto, 606-0001 Japan

You can participate in very active discussions and cutting‐edge lectures by the world’s top scientists and neurologists including three Nobel laureates as well as hear all the advances of scientific and clinical neurology. Gene therapy and stem/ iPS cell medicine are such examples on the one hand and Brain‐Machine‐Interface, information technology and robotics in care and rehabilitation on the other. Neurology related to environmental and disaster medicine will also attract many neurologists particularly in rapidly developing counties.

Find out more »

AES Seed Grant Program 

September 22

Sponsor: American Epilepsy Society
Due Date: September 22, 2017
Award: Seed Grants may provide up to $20,000 for one year for direct costs only, and they may not be renewed. Examples of allowable costs include research project supplies and expenses related to information and technology exchange, such as travel for postdoctoral fellows between collaborating laboratories. The number of awards made each year is contingent on available funds.

Find out more »

AES Seed Grant Program 

September 22

Sponsor: American Epilepsy Society
Due Date: September 22, 2017
Award: The AES Seed Grant Program provides support to established investigators to pursue new and innovative directions in epilepsy research, bring new research methods to their research programs, or begin new collaborations with other investigators in epilepsy or in different, complementary disciplines. Seed Grants may provide up to $20,000 for one year for direct costs only, and they may not be renewed.

Find out more »

Cycle 3: The Midlife in the United States Study (U19)

September 25

Sponsor: National Institutes of Health
Due Date: September 25, 2017 by 5 pm local time of applicant organization
Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Find out more »

Cycle 3: Ruth L. Kirschstein National Research Service Awards (T Series)

September 25

Sponsor: National Institutes of Health
Due Date: September 25, 2017
Award: Training grants

Find out more »
+ Export Events